Loading stock…

IRADIMED CORPORATION (IRMD) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

IRADIMED CORPORATION

IRMDMarket cap $1.08BPrice $84.8

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes MRI-compatible IV pumps and patient monitors that actually work inside powerful magnetic fields, where normal medical devices fail completely. It's a niche it basically owns, supplying hospitals worldwide with equipment that keeps critical patients safe during scans.

In Bastion Portfolios?

52W Return+17%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+16%8

Revenue Forecast

Rev CAGR (1y)+9%6

Rev CAGR (3y)+11%7

Rev CAGR (5y)+12%8

Earnings Forecast

EPS Growth Y+1+20%8

EPS Growth Y+2+15%8

EPS Growth Y+3+12%7

Quality

Margins

EBIT Margin32%9

Net Income Margin27%9

Free Cash Flow Margin29%9

Debt

Net Debt/EBITDA-2.010

Efficiency

ROE24%8

ROA21%10

Earnings Stability1010

GEAR+VERY STRONG94

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)362

P/E Ratio (Forward 3y)311

P/BV10.52

EV Multiples

EV/EBITDA Fwd311

EV/EBIT Fwd342

Yield

Free Cash Flow Yield2.4%4

Dividend Yield0.9%3

Momentum

Short term

1 month return+2%8

3 month return-15%2

YTD return-12%3

Mid term

Price vs 52wHigh79%5

1 year return+16%6

Long term

3 year return+113%8

5 year return+166%8

Risk Shield

Price Risk

Beta0.67

Volatility31%7

Free Cash Flow

Free Cash Flow Margin29%9

Free Cash Flow Yield2.4%4

Quality

ROCE27%9

Earnings Stability1010

Net Debt/EBITDA-2.010

02Growth

Is it actually growing, and how fast?

IRMDIRADIMED

Revenue FY25$84M

GROWTH RATING↗

STRONG72 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+20%8

EPS growth, FY27E+15%8

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 72% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 15%/yr vs revenue 11%/yr).

WATCH

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 11%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE55 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return-15%2

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high79%5

1-year return+16%6

3-year return+113%8

5-year return+166%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +113% over three years and +166% over five, ahead of 70% of the market.

Strong recent results. The stock is outperforming over the past month (+2%).

WATCH

It's up 16% over the past year, but 21% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

The stock is underperforming over three months (-15%) and so far this year (-12%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the stock is underperforming over three months and so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on IRADIMED CORPORATION. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

IRMDIRADIMED

Revenue FY25$84M

GROWTH RATING↗

STRONG72 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+16%8

Revenue, next 1Y+9%6

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+20%8

EPS growth, FY27E+15%8

EPS growth, FY28E+12%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 72% of companies worldwide.

Revenue grew 16%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow in step with sales (EPS about 15%/yr vs revenue 11%/yr).

WATCH

Revenue grew 16%/yr over the last 3 years; forecasts see it cooling to 11%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE55 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+2%8

3-month return-15%2

YTD return-12%3

MID & LONG-TERM▾SCORE

% of 52-week high79%5

1-year return+16%6

3-year return+113%8

5-year return+166%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +113% over three years and +166% over five, ahead of 70% of the market.

Strong recent results. The stock is outperforming over the past month (+2%).

WATCH

It's up 16% over the past year, but 21% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

The stock is underperforming over three months (-15%) and so far this year (-12%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on IRADIMED CORPORATION. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community